Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review

Autor(es):Mostrar menos -

Encinas, Jessica Freitas Araujo ^[1] ; Peiro, Carlos Henrique Foncesca ^[1] ; Perez, Matheus Moreira ^[1] ; Raimundo, Joyce Regina Santos ^[1] ; de Gois, Katharyna Cardoso ^[1] ; Peres, Marina Cristina ^[1] ; Draghi, Patricia Ferrante ^[1] ; Arcia, Catherine Giovanna Costas ^[1] ; Simoes, Diogo Pimenta ^{[1, 2]} ; Murad, Neif ^[3] ; Alves, Beatriz da Costa Aguiar ^[1] ; Fonseca, Fernando Luiz Affonso ^{[1, 4]} ; da Veiga, Glaucia Luciano ^[1]

Afiliação do(s) autor(es)

^[1] Ctr Univ Saude ABC FMABC, Lab Anal Clin, Santo Andre, SP - Brazil

^[2] Univ Municipal Sao Caetano Do Sul USCS, Sao Caetano do Sul - Brazil

^[3] Ctr Univ Saude ABC FMABC, Setor Cardiol, Santo Andre, SP - Brazil

^[4] Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Campus Diadema, Diadema - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: European Journal of Pharmacology; v. 905, AUG 15 2021.
• Citações Web of Science: 0

Resumo

Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of the main risk factors for major adverse cardiovascular events (MACE), which are the leading causes of morbidity and mortality worldwide. The pharmacological treatment of SAH involves five main classes of drugs, and Nebivolol (NEB) is one of those drugs, belonging to the class of third generation 131-adrenoceptors selective blockers. NEB is composed of a racemic mixture of two enantiomers: d-nebivolol, which exerts antagonist effects on 131-adrenoceptors, and l-nebivolol, a vascular 133 receptor agonist. There are several studies that report different actions of NEB, not only for the treatment of SAH, but also as an antioxidant agent or even as a protector of renal damage. The aim of this systematic review was to investigate the available evidence regarding the effects of NEB on kidney diseases, evaluating its possible renoprotective action. (AU)

• Processo FAPESP: 18/24808-0 - Avaliação de marcadores de dano renal e perfil inflamatório em ratos idosos diabéticos
• Beneficiário: Glaucia Raquel Luciano da Veiga
• Modalidade de apoio: Auxílio à Pesquisa - Regular